Jae Park Explains CAR T-cell Therapy
Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
CAR T-cells are artificial T-cell receptors that are made by combining a domain from an antibody to the domain of a T-cell. This makes the therapy effective because it can signal and act like a T-cell and bind like an antibody, taking advantage of both bodies, Park explains. Also incorporating the T-cell allows the therapy to be a “living drug” that can grow and replicate, not limited by its determined half-life.
Oncology Nurses Provide Patients an Avenue to Supportive Care
August 2nd 2025Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that isn't the reality of what id can do for patients. And oncology nurses can help guide patients to the right supportive care for them.
Hyman B. Muss Discusses the Importance of Nurses in Treating Pregnant Women With Breast Cancer
August 2nd 2025Hyman B. Muss, MD, professor of medicine at the University of North Carolina School of Medicine, discusses the vital roles that nurses play when it comes to treating pregnant women with breast cancer.
